Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 Oct;38(5):2098-2105.
doi: 10.1016/j.clnu.2018.10.028. Epub 2018 Nov 10.

The effects of vitamin D and probiotic co-supplementation on glucose homeostasis, inflammation, oxidative stress and pregnancy outcomes in gestational diabetes: A randomized, double-blind, placebo-controlled trial

Mehri Jamilian  1 , Elaheh Amirani  2 , Zatollah Asemi  3
Affiliations
Randomized Controlled Trial

The effects of vitamin D and probiotic co-supplementation on glucose homeostasis, inflammation, oxidative stress and pregnancy outcomes in gestational diabetes: A randomized, double-blind, placebo-controlled trial

Mehri Jamilian et al. Clin Nutr. 2019 Oct.

Abstract

Background and aims: This study was designed to assess the effects of combined vitamin D and probiotic supplementation on metabolic status and pregnancy outcomes in women with gestational diabetes (GDM).

Methods: This randomized, double-blind, placebo-controlled clinical trial was performed in 87 women with GDM. Patients were randomly assigned three groups to receive either vitamin D (50,000 IU/every 2 weeks) plus probiotic (8 × 109 CFU/day) (n = 30), probiotic (8 × 109 CFU/day) (n = 29) or placebo (n = 28) for 6 weeks.

Results: Vitamin D and probiotic co-supplementation significantly reduced fasting plasma glucose (β -10.99 mg/dL; 95% CI, -14.26, -7.73; P < 0.001), serum insulin levels (β -1.95 μIU/mL; 95% CI, -3.05, -0.84; P = 0.001) and homeostasis model of assessment-insulin resistance (β -0.76; 95% CI, -1.06, -0.45; P < 0.001), and significantly increased the quantitative insulin sensitivity check index (β 0.01; 95% CI, 0.008, 0.03; P = 0.001) compared with the placebo. In addition, vitamin D and probiotic co-supplementation resulted in a significant reduction in triglycerides (β -37.56 mg/dL; 95% CI, -51.55, -23.56; P < 0.001), VLDL- (β -7.51 mg/dL; 95% CI, -10.31, -4.71; P < 0.001), HDL-/total cholesterol ratio (β -0.52; 95% CI, -0.79, -0.24; P < 0.001), high sensitivity C-reactive protein (β -1.80 mg/L; 95% CI, -2.53, -1.08; P < 0.001) and malondialdehyde (β -0.43 μmol/L; 95% CI, -0.77, -0.09; P = 0.01); also, a significant rise in HDL-cholesterol (β 4.09 mg/dL; 95% CI, 1.11, 7.08; P = 0.008) and total antioxidant capacity (TAC) levels (β 97.77 mmol/L; 95% CI, 52.34, 143.19; P < 0.001) were observed compared with the placebo. Vitamin D and probiotic co-supplementation did not change other metabolic parameters. Vitamin D and probiotic co-supplementation significantly decreased triglycerides (P = 0.02), VLDL-cholesterol (P = 0.02) and hs-CRP (P = 0.01), and significantly increased TAC (P = 0.006) and total glutathione levels (P = 0.04) compared with only probiotic group.

Conclusions: In conclusion, vitamin D and probiotic co-supplementation in women with GDM had beneficial effects on metabolic status. This trial was registered at www.irct.ir as IRCT201706075623N119.

Keywords: Gestational diabetes; Pregnant women; Supplementation.

PubMed Disclaimer

Publication types